BIOQUEST CORP (BQST) Financials
Newest figures come from the 10-Q for Q1 FY2023, filed Sep 12, 2022. Each column of the statement tables below links to the filing it was taken from.
This page shows BIOQUEST CORP (BQST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BIOQUEST CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q1 2023.
Cash & Balance Sheet
BIOQUEST CORP held $15K in cash as of Q1 2023; long-term debt is not reported for that period.
Not reported for Q1 2023.
Not reported for Q1 2023.
Margins & Returns
None of these metrics is reported for Q1 2023.
Capital Allocation
None of these metrics is reported for Q1 2023.
BQST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $2K-88.2% | N/A | N/A | N/A | $16K-59.5% | N/A | $44K+605.7% | $15K |
| Operating Income | -$50K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $24K-47.5% | N/A | N/A | $13K+1073.1% | $45K+7441.8% | N/A | $17K | $1K |
| EPS (Basic) | -$0.01+80.0% | -$0.02+74.4% | $0.00+105.0% | -$0.02+75.0% | -$0.05-25.0% | -$0.08 | -$0.08 | -$0.08 |
| EPS (Diluted) | N/A | N/A | $0.00+105.0% | N/A | N/A | N/A | -$0.08 | N/A |
| Diluted Shares (Avg) | N/A | N/A | 12M+38.8% | N/A | N/A | N/A | 8M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Income Tax, Net Income.
BQST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15K+5.5% | $34K+96.2% | $116-99.5% | $7K-57.9% | $14K | $17K+10199.4% | $22K | $16K |
| Current Assets | $15K+5.5% | $34K+96.2% | $116-99.5% | $7K-57.9% | $14K | $17K+10199.4% | $22K | $16K |
| Cash & Equivalents | $15K+446.6% | $34K+12800.0% | $116+93.3% | $818+1068.6% | $3K | $260+56.6% | $60 | $70 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $551K-74.4% | $467K-73.9% | $394K-73.2% | $451K-45.0% | $2.2M | $1.8M+1187.7% | $1.5M | $819K |
| Current Liabilities | $551K-74.4% | $467K-73.9% | $394K-72.4% | $451K-42.2% | $2.2M | $1.8M+1709.3% | $1.4M | $779K |
| Non-Current Liabilities | $0 | $0 | $0-100.0% | $0-100.0% | $0 | $0-100.0% | $40K | $40K |
| Total Equity | -$536K+75.0% | -$433K+75.5% | -$394K+72.8% | -$444K+44.8% | -$2.1M-493.6% | -$1.8M-1176.9% | -$1.4M-21463.2% | -$803K-6760.5% |
| Retained Earnings | -$10.8M-4.9% | -$10.7M-8.3% | -$10.4M-2547.3% | -$10.5M-223.6% | -$10.3M | -$9.8M-30.9% | -$394K | $8.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BQST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19K+70.3% | -$52K-911.3% | N/A | -$2K+96.0% | -$63K+35.9% | -$5K | -$43K+26.2% | -$48K |
| Stock-Based Compensation | N/A | N/A | N/A | $17K-88.9% | N/A | N/A | N/A | $150K |
| Financing Cash Flow | N/A | $85K+1503.8% | $0-100.0% | $0-100.0% | $65K-35.0% | $5K | $43K-64.2% | $45K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
BQST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$433K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIOQUEST CORP BQST | FY2022 | N/A | N/A | N/A | $2.0M | — |
| HALLMARK VENTURE GRP INC HLLK | FY2025 | N/A | N/A | N/A | $99.3M | — |
| TREX ACQUISITION CORP TRXA | FY2025 | $32K | -$2.5M | N/A | $19.6M | — |
Where BIOQUEST CORP Ranks
Frequently Asked Questions
What is BIOQUEST CORP's operating cash flow?
BIOQUEST CORP (BQST) recorded an outflow of $117K in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are BIOQUEST CORP's total assets?
BIOQUEST CORP (BQST) had $34K in total assets as of fiscal year 2022, including both current and long-term assets.
What is BIOQUEST CORP's current ratio?
BIOQUEST CORP (BQST) had a current ratio of 0.07 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
Why is BIOQUEST CORP's debt-to-equity ratio negative or not reported?
BIOQUEST CORP (BQST) has negative shareholder equity of -$433K as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.